Gilead Sciences (GILD) Tops Q2 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Gilead Sciences (GILD) PT Raised to $85 at Morgan Stanley
July 26, 2018 8:53 AM EDTMorgan Stanley raised its price target on Gilead Sciences (NASDAQ: GILD) to $85.00 (from $81.00) while maintaining a Equalweight rating.
... MoreGilead Sciences (GILD) PT Raised to $90 at RBC Capital
July 26, 2018 7:58 AM EDTRBC Capital raised its price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $87.00) while maintaining an Outperform rating following results.
Analyst Brian Abraham commented, "With strong HIV sales and HCV stabilizing, GILD seems to be tracking towards steadier earnings base upon which... More
